Autologous stem-cell transplantation for multiple myeloma

New England Journal of Medicine

Volumn 361, Issue 11, 2009, Pages 1118-1119

  Louw, Vernon J ^a   Louw, Hymne ^a   Webb, Michael J ^a  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; HEMOGLOBIN;

ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CHROMOSOME DELETION 13; HUMAN; LETTER; MAJOR CLINICAL STUDY; MONOSOMY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

EID: 70149090635     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc091447     Document Type: Letter

References (5)

1. Harousseau J-L, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009;360:2645-2654
2. Paul E, Sutlu T, Deneberg S, et al. Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation. Oncol Rep 2009;22:137-142
3. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566-1571 (Pubitemid 32217218)
4. Zojer N, Königsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000;95:1925-1930 (Pubitemid 30151627)
5. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151-157 (Pubitemid 44921846)